Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Advances in Experimental Medicine and Biology
|
August 19, 2007
Cell-cycle inhibitor profiling by high-content analysis
Fabio Gasparri, Antonella Ciavolella, Arturo Galvani
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 6, 2006
Antitumor efficacy of edotecarin as a single agent and in combination with chemotherapy agents in a xenograft model
Marina Ciomei, Valter Croci, Antonella Ciavolella, et al.
Molecular Cancer Therapeutics
|
September 18, 2023
Novel Thienoduocarmycin-Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies
Barbara Valsasina, Paolo Orsini, Michele Caruso, et al.
Chempluschem
|
January 29, 2020
9-Fluorenone-2-Carboxylic Acid as a Scaffold for Tubulin Interacting Compounds
Francesco Calogero, Stella Borrelli, Gaetano Speciale, et al.
Journal of Medicinal Chemistry
|
June 27, 2009
Cell division cycle 7 kinase inhibitors: 1H-pyrrolo[2,3-b]pyridines, synthesis and structure-activity relationships
Antonella Ermoli, Alberto Bargiotti, Maria Gabriella Brasca, et al.
Journal of Medicinal Chemistry
|
January 19, 2008
Cdc7 kinase inhibitors: pyrrolopyridinones as potential antitumor agents. 1. Synthesis and structure-activity relationships
Ermes Vanotti, Raffaella Amici, Alberto Bargiotti, et al.
Molecular Cancer Therapeutics
|
February 10, 2012
NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies
Barbara Valsasina, Italo Beria, Cristina Alli, et al.
Nature Chemical Biology
|
May 13, 2008
A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity
Alessia Montagnoli, Barbara Valsasina, Valter Croci, et al.
Journal of Medicinal Chemistry
|
April 20, 2010
Identification of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitors
Italo Beria, Dario Ballinari, Jay Aaron Bertrand, et al.
Journal of Medicinal Chemistry
|
January 1, 2009
First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery
Maria Menichincheri, Alberto Bargiotti, Jens Berthelsen, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Advances in Experimental Medicine and Biology
|
August 19, 2007
Cell-cycle inhibitor profiling by high-content analysis
Fabio Gasparri, Antonella Ciavolella, Arturo Galvani
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 6, 2006
Antitumor efficacy of edotecarin as a single agent and in combination with chemotherapy agents in a xenograft model
Marina Ciomei, Valter Croci, Antonella Ciavolella, et al.
Molecular Cancer Therapeutics
|
September 18, 2023
Novel Thienoduocarmycin-Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies
Barbara Valsasina, Paolo Orsini, Michele Caruso, et al.
Chempluschem
|
January 29, 2020
9-Fluorenone-2-Carboxylic Acid as a Scaffold for Tubulin Interacting Compounds
Francesco Calogero, Stella Borrelli, Gaetano Speciale, et al.
Journal of Medicinal Chemistry
|
June 27, 2009
Cell division cycle 7 kinase inhibitors: 1H-pyrrolo[2,3-b]pyridines, synthesis and structure-activity relationships
Antonella Ermoli, Alberto Bargiotti, Maria Gabriella Brasca, et al.
Journal of Medicinal Chemistry
|
January 19, 2008
Cdc7 kinase inhibitors: pyrrolopyridinones as potential antitumor agents. 1. Synthesis and structure-activity relationships
Ermes Vanotti, Raffaella Amici, Alberto Bargiotti, et al.
Molecular Cancer Therapeutics
|
February 10, 2012
NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies
Barbara Valsasina, Italo Beria, Cristina Alli, et al.
Nature Chemical Biology
|
May 13, 2008
A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity
Alessia Montagnoli, Barbara Valsasina, Valter Croci, et al.
Journal of Medicinal Chemistry
|
April 20, 2010
Identification of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitors
Italo Beria, Dario Ballinari, Jay Aaron Bertrand, et al.
Journal of Medicinal Chemistry
|
January 1, 2009
First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery
Maria Menichincheri, Alberto Bargiotti, Jens Berthelsen, et al.
Page
of 2